8.625

7.54% 0.605

Sagimet Biosciences Inc (SGMT)

Overview News Price History Option Chain Financials Discussions Forecast

Sagimet Biosciences Inc stock is traded at $8.625, with a volume of 586.01K. It is up +7.54% in the last 24 hours and down -17.54% over the past month. Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Previous Close:

$8.02

Open:

$8.24

24h Volume:

586.01K

Relative Volume:

0.44

Market Cap:

$611.59M

Revenue:

$2.00M

Net Income/Loss:

$-43.51M

P/E Ratio:

-6.4294

EPS:

-1.3415

Net Cash Flow:

$-39.73M

1W Performance:

-3.42%

1M Performance:

-17.54%

6M Performance:

+39.34%

1Y Performance:

+14.24%

1-Day Range:

$8.15

$8.68

1-Week Range:

$7.51

$8.74

52-Week Range:

$4.50

$11.45

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name

Sagimet Biosciences Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

(650) 561-8600

Address

155 BOVET RD., SUITE 303, SAN MATEO

Employee

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

SGMT's Discussions on Twitter

Compare SGMT vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMT Sagimet Biosciences Inc	8.625	611.59M	2.00M	-43.51M	-39.73M	-1.3415
VRTX Vertex Pharmaceuticals Inc	504.79	127.94B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	223.99	89.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	785.09	80.83B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	827.18	52.02B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.16	41.99B	5.76B	514.49M	1.10B	4.4813

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-24-26	Resumed	Goldman	Sell
Sep-09-26	Upgrade	Barclays	Equal Weight → Overweight
Sep-09-26	Initiated	Cantor Fitzgerald	Overweight
Mar-26-26	Initiated	Rodman & Renshaw	Buy
Feb-03-26	Initiated	Guggenheim	Buy
Jan-28-26	Initiated	Barclays	Equal Weight
Aug-11-25	Initiated	Wedbush	Outperform
Aug-07-25	Resumed	H.C. Wainwright	Buy
Jul-24-25	Initiated	Canaccord Genuity	Buy
Dec-06-24	Initiated	Oppenheimer	Outperform
Nov-12-24	Initiated	UBS	Buy
Jun-28-24	Downgrade	Goldman	Buy → Neutral
May-02-24	Initiated	H.C. Wainwright	Buy
Mar-25-24	Initiated	Leerink Partners	Outperform
Aug-08-23	Initiated	Goldman	Buy
Aug-08-23	Initiated	JMP Securities	Mkt Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight
Aug-08-23	Initiated	TD Cowen	Outperform

View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

Oct 09, 2026

Sagimet reports 57% IGA success at Week 52 - grafa.com

Oct 09, 2026